Skip Nav Destination
Issues
1 March 2015
-
Cover Image
Cover Image
The cover shows a section of a tumor biopsy from mice with the SW1 melanoma, which were treated with an anti-CTLA4/PD-1/CD137 mAb combination. Immunohistochemical staining shows a dramatic decrease of tumor-infiltrating CD19 cells. For details, see the article by Dai and colleagues on page 1127 of this issue. - PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265
Highlights
20th Anniversary Commentary
CCR Translations
CCR Perspectives in Drug Approval
FDA Approval: Siltuximab for the Treatment of Patients with Multicentric Castleman Disease
Albert Deisseroth; Chia-Wen Ko; Lei Nie; Jeanne F. Zirkelbach; Liang Zhao; Julie Bullock; Nitin Mehrotra; Pedro Del Valle; Haleh Saber; Christopher Sheth; Brenda Gehrke; Robert Justice; Ann Farrell; Richard Pazdur
Molecular Pathways
Reviews
Cancer Therapy: Clinical
A Phase I Study of Oral ARRY-614, a p38 MAPK/Tie2 Dual Inhibitor, in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes
Guillermo Garcia-Manero; Hanna J. Khoury; Elias Jabbour; Jeffrey Lancet; Shannon L. Winski; LouAnn Cable; Selena Rush; Lara Maloney; Grant Hogeland; Mieke Ptaszynski; Monica Cabrero Calvo; Zach Bohannan; Alan List; Hagop Kantarjian; Rami Komrokji
CDK 4/6 Inhibitor Palbociclib (PD0332991) in Rb+ Advanced Breast Cancer: Phase II Activity, Safety, and Predictive Biomarker Assessment
Angela DeMichele; Amy S. Clark; Kay See Tan; Daniel F. Heitjan; Kristi Gramlich; Maryann Gallagher; Priti Lal; Michael Feldman; Paul Zhang; Christopher Colameco; David Lewis; Melissa Langer; Noah Goodman; Susan Domchek; Keerthi Gogineni; Mark Rosen; Kevin Fox; Peter O'Dwyer
Author Choice
Phase I Dose-Escalation Trial of the Oral Investigational Hedgehog Signaling Pathway Inhibitor TAK-441 in Patients with Advanced Solid Tumors
Jonathan Goldman; S. Gail Eckhardt; Mitesh J. Borad; Kelly K. Curtis; Manuel Hidalgo; Emiliano Calvo; David P. Ryan; Lori J. Wirth; Asit Parikh; James Partyka; Helene Faessel; Esha Gangolli; Sally Stewart; Lee S. Rosen; Daniel W. Bowles
Angiogenic Cytokines Are Antibody Targets During Graft-versus-Leukemia Reactions
Matthias Piesche; Vincent T. Ho; Haesook Kim; Yukoh Nakazaki; Michael Nehil; Nasser K. Yaghi; Dmitriy Kolodin; Jeremy Weiser; Peter Altevogt; Helena Kiefel; Edwin P. Alyea; Joseph H. Antin; Corey Cutler; John Koreth; Christine Canning; Jerome Ritz; Robert J. Soiffer; Glenn Dranoff
A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1–Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response
Paul F. Robbins; Sadik H. Kassim; Thai L.N. Tran; Jessica S. Crystal; Richard A. Morgan; Steven A. Feldman; James C. Yang; Mark E. Dudley; John R. Wunderlich; Richard M. Sherry; Udai S. Kammula; Marybeth S. Hughes; Nicholas P. Restifo; Mark Raffeld; Chyi-Chia R. Lee; Yong F. Li; Mona El-Gamil; Steven A. Rosenberg
Personalized Medicine and Imaging
Nottingham Clinico-Pathological Response Index (NPRI) after Neoadjuvant Chemotherapy (Neo-ACT) Accurately Predicts Clinical Outcome in Locally Advanced Breast Cancer
Tarek M. Abdel-Fatah; Graham Ball; Andrew H.S. Lee; Sarah Pinder; R. Douglas MacMilan; Eleanor Cornford; Paul M. Moseley; Rafael Silverman; James Price; Bruce Latham; David Palmer; Arlene Chan; Ian O. Ellis; Stephen Y.T. Chan
Correlation of PD-L1 Tumor Expression and Treatment Outcomes in Patients with Renal Cell Carcinoma Receiving Sunitinib or Pazopanib: Results from COMPARZ, a Randomized Controlled Trial
Toni K. Choueiri; David J. Figueroa; André P. Fay; Sabina Signoretti; Yuan Liu; Robert Gagnon; Keith Deen; Christopher Carpenter; Peter Benson; Thai H. Ho; Lini Pandite; Paul de Souza; Thomas Powles; Robert J. Motzer
Gene Expression Markers of Efficacy and Resistance to Cetuximab Treatment in Metastatic Colorectal Cancer: Results from CALGB 80203 (Alliance)
Stephanie M. Cushman; Chen Jiang; Ace J. Hatch; Ivo Shterev; Alexander B. Sibley; Donna Niedzwiecki; Alan P. Venook; Kouros Owzar; Herbert I. Hurwitz; Andrew B. Nixon
Clinical Relevance of KRAS-Mutated Subclones Detected with Picodroplet Digital PCR in Advanced Colorectal Cancer Treated with Anti-EGFR Therapy
Pierre Laurent-Puig; Deniz Pekin; Corinne Normand; Steve K. Kotsopoulos; Philippe Nizard; Karla Perez-Toralla; Rachel Rowell; Jeff Olson; Preethi Srinivasan; Delphine Le Corre; Thevy Hor; Zakaria El Harrak; Xinyu Li; Darren R. Link; Olivier Bouché; Jean-François Emile; Bruno Landi; Valérie Boige; J. Brian Hutchison; Valerie Taly
Circulating Tumor Cell Analysis in Metastatic Triple-Negative Breast Cancers
Mark Jesus M. Magbanua; Lisa A. Carey; Amy DeLuca; Jimmy Hwang; Janet H. Scott; Mothaffar F. Rimawi; Erica L. Mayer; P. Kelly Marcom; Minetta C. Liu; Francisco J. Esteva; John W. Park; Hope S. Rugo; for the Translational Breast Cancer Research Consortium; for the Translational Breast Cancer Research Consortium; for the Translational Breast Cancer Research Consortium; for the Translational Breast Cancer Research Consortium; for the Translational Breast Cancer Research Consortium; for the Translational Breast Cancer Research Consortium; for the Translational Breast Cancer Research Consortium; for the Translational Breast Cancer Research Consortium; for the Translational Breast Cancer Research Consortium; for the Translational Breast Cancer Research Consortium; for the Translational Breast Cancer Research Consortium; for the Translational Breast Cancer Research Consortium
Author Choice
Neuregulin 1 Expression Is a Predictive Biomarker for Response to AV-203, an ERBB3 Inhibitory Antibody, in Human Tumor Models
Kristan Meetze; Sylvie Vincent; Steven Tyler; Elizabeth K. Mazsa; Andrea R. Delpero; Steve Bottega; Donna McIntosh; Richard Nicoletti; William M. Winston; Solly Weiler; Bin Feng; Jeno Gyuris; Zhigang Weng
Cancer Therapy: Preclinical
Activity of MM-398, Nanoliposomal Irinotecan (nal-IRI), in Ewing's Family Tumor Xenografts Is Associated with High Exposure of Tumor to Drug and High SLFN11 Expression
Min H. Kang; Jing Wang; Monish R. Makena; Joo-Sang Lee; Nancy Paz; Connor P. Hall; Michael M. Song; Ruben I. Calderon; Riza E. Cruz; Ashly Hindle; Winford Ko; Jonathan B. Fitzgerald; Daryl C. Drummond; Timothy J. Triche; C. Patrick Reynolds
Author Choice
Radiotherapy Combined with the Immunocytokine L19-IL2 Provides Long-lasting Antitumor Effects
Catharina M.L. Zegers; Nicolle H. Rekers; Dana H.F. Quaden; Natasja G. Lieuwes; Ala Yaromina; Wilfred T.V. Germeraad; Lotte Wieten; Erik A.L. Biessen; Louis Boon; Dario Neri; Esther G.C. Troost; Ludwig J. Dubois; Philippe Lambin
Patient-Derived Xenografts from Non–Small Cell Lung Cancer Brain Metastases Are Valuable Translational Platforms for the Development of Personalized Targeted Therapy
Hye Won Lee; Jung-il Lee; Se Jeong Lee; Hyun Jung Cho; Hye Jin Song; Da Eun Jeong; Yun Jee Seo; Sang Shin; Je-Gun Joung; Yong-Jun Kwon; Yoon-La Choi; Woong-Yang Park; Hyun Moo Lee; Ho Jun Seol; Young Mog Shim; Kyeung Min Joo; Do-Hyun Nam
Biology of Human Tumors
Sonic Hedgehog and Gli1 Expression Predict Outcome in Resected Pancreatic Adenocarcinoma
Raphaël Maréchal; Jean-Baptiste Bachet; Annabelle Calomme; Pieter Demetter; Jean Robert Delpero; Magali Svrcek; Jérôme Cros; Armelle Bardier-Dupas; Francesco Puleo; Geneviève Monges; Pascal Hammel; Christophe Louvet; François Paye; Philippe Bachelier; Yves Patrice Le Treut; Jean-Christophe Vaillant; Alain Sauvanet; Thierry André; Isabelle Salmon; Jacques Devière; Jean-François Emile; Jean-Luc Van Laethem
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds